Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
VICTOZA - adult type 2 diabetes dosing and renal statement
Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal method
No renal-function dose bands specified for this summary.
Source revision
DailyMed updated 2025-10-14.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Official
VICTOZA - adult type 2 diabetes dosing and renal statement
NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal method: No renal-function dose bands specified for this summary. Source date: DailyMed updated 2025-10-14. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
Begin 0.6 mg subcutaneously daily for one week to improve gastrointestinal tolerance, then 1.2 mg daily. If needed, increase to 1.8 mg daily after at least one week on 1.2 mg. The 0.6-mg adult dose is for initiation, not effective glycemic maintenance.
No renal dose adjustment is recommended; ESRD experience is limited. Review dehydration/acute-kidney-injury risk with gastrointestinal adverse effects. Medullary thyroid carcinoma/MEN2 contraindications remain applicable. This diabetes product regimen is not the SAXENDA weight-management regimen.
RDM30-086-liraglutide-victoza-1 · Source locator: VICTOZA - adult type 2 diabetes dosing and renal statement; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.